Takeda, Endo Face New Pay-To-Delay Suit

The operator of Kinney Drugs retail chain sued Takeda Pharmaceutical and Endo International over claims that the pharmaceutical manufacturers allegedly engaged in a pay-to-delay scheme to keep generic versions of Takeda’s anti-constipation drug Amitiza off the market.

Related: Takeda Wants 2nd Circuit To Toss Actos Antitrust Suit

KPH Healthcare Services’ antitrust lawsuit, filed Tuesday, August 3, in the US District Court for the District of Massachusetts, claimed that Japan-based Takeda and its US subsidiary, Takeda Pharmaceuticals USA, made “reverse payments” totaling between US$29 and US$280 million to an Endo subsidiary, Par Pharmaceuticals, to keep the generic from being introduced for over six years.

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.